$MDXG (MiMedx Group, Inc.)

$MDXG {{ '2016-04-11T13:03:31+0000' | timeago}} • Announcement

Regenerative medicine company $MDXG reported a 31% increase in 1Q16 revenue when compared to a year ago. This revenue increase was helped by a YoverY growth in its Surgical, Sports Medicine and Orthopedics revenue of 28%, as well as a 32% growth in Wound Care revenue.

$MMM {{ '2017-07-25T17:59:58+0000' | timeago}} • Webcast

$MMM said it had reduced prices of a number of products in 2Q17 to accelerate growth in areas where price seemed to be a barrier. The St Paul, Minnesota-based company added that it is currently at the peak of price declines and expects an upstick in pricing in 2H17.

$MMM {{ '2017-07-25T17:38:50+0000' | timeago}} • Webcast

$MMM, which makes Post-It notes, said it saw organic growth in three of its four Consumer segment businesses in 2Q17, namely Home Improvement, Home Supplies and Consumer Healthcare. Meanwhile, its Stationery and Office Supplies business was again impacted by inventory reductions in the US office retail and wholesale channels.

$MMM {{ '2017-07-25T17:23:43+0000' | timeago}} • Webcast

$MMM said it expects 20-25 cents per share impact from incremental strategic investments in 2H17, which is expected to drive greater productivity from its manufacturing and supply chain base.

$MMM {{ '2017-07-25T13:22:56+0000' | timeago}} • Infographic

$MMM 3M Earnings AlphaGraphic: Q2 2017 Highlights

$MMM {{ '2017-07-25T12:44:59+0000' | timeago}} • Announcement

On a geographic basis, $MMM saw highest growth in Asia Pacific region in 2Q17, where sales grew 8.3%. In other locations, sales increased 2.5% in Latin America/Canada, and 0.5% in the US. Meanwhile, total sales declined 3.6% in EMEA.

$MMM {{ '2017-07-25T12:41:50+0000' | timeago}} • Announcement

In 2Q17, $MMM's sales grew 7.5% in Electronics and Energy, 2.5% in Industrial and 1.8% in Health Care. Consumer continued to be an area of concern, where the company managed just 0.5% growth. Meanwhile, sales declined 0.9% in Safety and Graphics segment.

$MMM {{ '2017-07-25T12:23:15+0000' | timeago}} • Announcement

$MMM raised the lower end of its FY17 EPS outlook. It now expects GAAP EPS of $8.80-9.05, compared to the earlier forecast of $8.70-9.05.

$MMM {{ '2017-07-25T12:16:01+0000' | timeago}} • Announcement

Manufacturing company $MMM reported 24% jump in EPS to $2.58 in 2Q17, as sales inched up 2% to $7.8Bil. The sales growth was driven by its Electronics and Energy segment, as well as the Asia Pacific operations. Net income attributable to 3M was $1.58Bil, compared to $1.29Bil a year ago. Operating margin grew 3.6 percentage points to 28%.

$JNJ {{ '2017-07-24T17:21:48+0000' | timeago}} • Announcement

$JNJ said preliminary data from a phase 1/2a clinical trial on an investigational HIV-1 vaccine regimen showed positive results in a sample of 393 healthy volunteers. If the vaccine clears the phase 3 trials, its launch can be expected within a decade. There are currently around 37MM AIDS patients around the world.

$TFX {{ '2017-07-24T12:12:24+0000' | timeago}} • Announcement

$TFX said its Arrow Seldinger Arterial Catheterization Device received market clearance from the U.S. Food and Drug Administration (FDA). The new Seldinger Arterial Catheterization Device is indicated for short-term use. $TFX expects to launch the Arrow Seldinger Arterial Catheterization Device in US this year.

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

$JNJ {{ '2017-07-18T11:59:48+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphics: Q2 2017 highlights

$JNJ {{ '2017-07-18T11:26:59+0000' | timeago}} • Announcement

Medical Devices segment was the top performer for $JNJ in 2Q17, with a growth of 4.9%. While Consumer segment added to this with a 1.7% growth, Pharmaceutical segment edged down 0.2%.

$JNJ {{ '2017-07-18T11:19:55+0000' | timeago}} • Announcement

$JNJ CEO Alex Gorsky said, "Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA as well as the submission and approval of several key line extensions. We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year."

$JNJ {{ '2017-07-18T11:14:25+0000' | timeago}} • Announcement

$JNJ, which recently acquired Actelion Ltd for $30Bil, raised its sales guidance for FY17 to $75.8-76.1Bil. Additionally, the New Brunswick, NJ - based company raised its adjusted earnings guidance for the same period to $7.12-7.22 per share.

$JNJ {{ '2017-07-18T11:08:14+0000' | timeago}} • Announcement

Pharmaceutical giant $JNJ reported growth in sales and adjusted EPS in 2Q17. While sales increased 2% to $18.8Bil riding on International sales growth of 2.3%, adjusted EPS stood at $1.83, representing an increase of 3.1%. On a GAAP basis, net earnings were down to $3.8Bil, or $1.40 per share, compared to $4Bil, or $1.43 per share, a year ago.

$JNJ {{ '2017-07-17T15:58:16+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 3Q17 of $0.84 per share on its common stock. The dividend is payable on September 12, 2017 to shareholders of record as on August 29, 2017. The ex-dividend date is August 25, 2017.

Recent Transcripts

MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
CAH (Cardinal Health, Inc.)
Monday, May 1 2017 - 12:30pm
MDXG (MiMedx Group, Inc.)
Friday, April 28 2017 - 2:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, April 26 2017 - 12:30pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
MMM (3M Company)
Tuesday, April 25 2017 - 1:00pm

AlphaGraphics you may like